Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: Profiling and comparison of two drug compendia

Annals of Pharmacotherapy

Volumn 42, Issue 12, 2008, Pages 1737-1748

  Wong, Chen May ^a   Ko, Yu ^c   Chan, Alexandre ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c NONE

Author keywords

Drug compendia; Drug information; Drug drug interactions

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BARBITURIC ACID DERIVATIVE; BUSULFAN; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CHLORAMBUCIL; CHOLINESTERASE INHIBITOR; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; HORMONE ANTAGONIST; HYDANTOIN DERIVATIVE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMYCIN; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; THYROID HORMONE; UNINDEXED DRUG; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ARTICLE; CANCER THERAPY; DRUG ANTAGONISM; DRUG INFORMATION; DRUG POTENTIATION; PRIORITY JOURNAL;

EID: 84984534151     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L255     Document Type: Article

References (165)

1. Karas S Jr. The potential for drug interactions. Ann Emerg Med 1981;10:627-30.
2. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007;99:592-600.
3. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007;32:169-75.
4. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007;64(suppl 5):S4-7.
5. Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest 2006;24:704-12.
6. Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 2004;44:136-41.
7. Fulda TR, Valuck RJ, Zanden JV, Parker S, Byrns PJ. Disagreement among drug compendia on inclusion and rating of drug-drug interactions. Curr Ther Res 2000;61:540-8.
8. Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007;63:709-14.
9. Tatro DS. Drug interaction facts. In: Facts and comparisons. St. Louis: Wolters Kluwer, 2008.
10. DRUGDEX System [intranet database]. Version 5.1. Greenwood Village, CO: Thomson Healthcare, 2007 Oct.
11. Singleton JD, Conyers L. Warfarin and azathioprine: an important drug interaction. Am J Med 1992;92:217.
12. Rivier G, Khamashta MA, Hughes GR. Warfarin and azathioprine: a drug interaction does exist. Am J Med 1993;95:342.
13. Rotenberg M, Levy Y, Shoenfeld Y, Almog S, Ezra D. Effect of azathioprine on the anticoagulant activity of warfarin (letter). Ann Pharmacother 2000;34:120-2. DOI 10.1345/aph.19148
14. Havrda DE, Rathbun S, Scheid D. A case report of warfarin resistance due to azathioprine and review of the literature. Pharmacotherapy 2001;21:355-7.
15. Levine AS, Sharp HL, Mitchell J, Krivit W, Nesbit ME. Combination therapy with 6-mercaptopurine (NSC-755) and allopurinol (NSC-1390) during induction and maintenance of remission of acute leukemia in children. Cancer Chemother Rep 1969;53:53-7.
16. Nies AS, Oates JA. Clinicopathologic conference: hypertension and the lupus syndrome - revisited. Am J Med 1971;51:812-4.
17. Berns A, Rubenfeld S, Rymzo WT Jr, Calabro JJ. Hazard of combining allopurinol and thiopurine. N Engl J Med 1972;286:730-1.
18. Zazgornik J, Kopsa H, Schmidt P, Pils P, Kuschan K, Deutsch E. Increased danger of bone marrow damage in simultaneous azathioprine-allopurinol therapy. Int J Clin Pharmacol Ther Toxicol 1981;19:96-7.
19. Brooks RJ, Dorr RT, Durie BG. Interaction of allopurinol with 6-mercaptopurine and azathioprine. Biomed Pharmacother 1982;36:217-22.
20. Krowka MJ, Breuer RI, Kehoe TJ. Azathioprine-associated pulmonary dysfunction. Chest 1983;83:696-8.
21. Zimm S, Collins JM, O'Neill D, Chabner BA, Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983;34:810-7.
22. Boyd IW. Allopurinol-azathioprine interaction. J Intern Med 1991;229:386.
23. Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 1996;61:1661-2.
24. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996;30:951-4. Epub 12 Jul 2005. DOI 10.1345/aph.1G153
25. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
26. Nilsson C, Aschan J, Hentschke P, Ringden O, Ljungman P, Hassan M. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;31:429-35.
27. Product information. Myleran tablets (busulfan). Research Triangle Park. NC: GlaxoSmithKline,2005.
28. Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996;16:2083-8.
29. Product information. Xeloda (capecitabine). Nutley, NJ: Roche Laboratories, Inc., 2001.
30. Copur MS, Ledakis P, Bolton M, et al. An adverse interaction between warfarin and capecitabine: a case report and review of the literature. Clin Colorectal Cancer 2001;1:182-4.
31. Camidge R, Reigner B, Cassidy J, et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 2005;23:4719-25.
32. Janney LM, Waterbury NV. Capecitabine-warfarin interaction. Ann Pharmacother 2005;39:1546-51.
33. Yildirim Y, Ozyilkan O, Akcali Z, Basturk B. Drug interaction between capecitabine and warfarin: a case report and review of the literature. Int J Clin Pharmacol Ther 2006;44:80-2.
34. Kuhlmann J, Zilly W, Wilke J. Effects of cytostatic drugs on plasma level and renal excretion of beta-acetyldigoxin. Clin Pharmacol Ther 1981;30:518-27.
35. Bjornsson TD, Huang AT, Roth P, Jacob DS, Christenson R. Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations. Clin Pharmacol Ther 1986;39:25-8.
36. Wang RI, Ross CA. Prolonged apnea following succinylcholinc in cancer patients receiving AB-132. Anesthesiology 1963;24:363-7.
37. Mone JG, Mathie WE. Qualitative defects of pseudocholinesterase activity. Anaesthesia 1967;22:55-68.
38. Gurman GM. Prolonged apnea after succinylcholine in a case treated with cytostatics for cancer. Anesth Analg 1972;51:761-5.
39. Zsigmond EK, Robins G. The effect of a series of anti-cancer drugs on plasma cholinesterase activity. Can Anaesth Soc J 1972;19:75-82.
40. Dillman JB. Safe use of succinylcholine during repeated anesthetics in a patient treated with cyclophosphamide. Anesth Analg 1987;66:351-3.
41. Esther V, Jaap V, Schellens J. Antineoplastic agents: drug interactions of clinical significance. Drug Saf 1995;12(3):168-83.
42. Walker IR, Zapf PW, Mackay IR. Cyclophosphamide, Cholinesterase and anaesthesia. Aust N Z J Med 1972;2:247-51.
43. Product information. Tarceva (erlotinib). Seymour, IN: Schwarz Pharma Manufacturing, 2006.
44. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase 1 trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-42.
45. Yahanda AM, Alder KM, Fisher GA, et al. Phase 1 trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992;10:1624-34.
46. Lum BL, Fisher GA, Brophy NA, et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 1993;72:3502-14.
47. Lum BL, Kaubisch S, Fisher GA, Brown BW, Sikic BI. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDRI gene) mediated drug resistance. Cancer Chemother Pharmacol 2000;45:305-11.
48. Lacayo NJ, Lum BL, Becton DL, et al. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 2002;16:920-7.
49. Onoda S, Mitsufuji H, Yanase N, et al. Drug interaction between gefitinib and warfarin. Jpn J Clin Oncol 2005;35:478-82.
50. Product information. Iressa (gefitinib). Macclesfield, Cheshire, UK: AstraZeneca UK Limited, 2005.
51. Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005;44:1067-81.
52. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004;53:102-6.
53. Product information. Gleevec (imatinib mesylate). East Hanover, NJ: Novartis, 2006.
54. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005;78:433-8.
55. de Groot JW, Links TP, van der Graaf WT. Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol 2006;17:1719-20.
56. Spiers AS, Mibashan RS. Increased warfarin requirement during mercaptopurine therapy: a new drug interaction (letter). Lancet 1974;2:221-2.
57. Martini A, Jahnchen E. Studies in rats on the mechanism by which 6-mercaptopurine inhibits the anticoagulant effect of warfarin. J Pharmacol Exp Ther 1977;201:547-53.
58. Martin LA, Mehta SD. Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy. Pharmacotherapy 2003;23:260-4.
59. Elion GB, Callahan S, Rundles RW, Hitchings GH. Relationship between metabolic fates and antitumor activities of thiopurines. Cancer Res 1963;23:1207-17.
60. Weissman AM, Christian DG, Cornelis WA, Fortner CL. Allopurinol- mercaptopurine interaction. J Am Pharm Assoc 1973;13:2.
61. Duley JA, Chocair PR, Florin TH. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine. Aliment Pharmacol Ther 2005;22:1161-2.
62. Ng HW, Macfarlane AW, Graham RM, Verbov JL. Near fatal drug interactions with methotrexate given for psoriasis. Br Med J (Clin Res Ed) 1987;295:752-3.
63. Govert JA, Patton S, Fine RL. Pancytopenia from using trimethoprim and methotrexate. Ann Intern Med 1992;117:877-8.
64. Steuer A, Gumpel JM. Methotrexate and trimethoprim: a fatal interaction. Br J Rheumatol 1998;37:105-6.
65. Riva R, Albani F, Baruzzi A. On the interaction between phenytoin and antineoplastic agents (letter). Ther Drug Monit 1985;7:123-6.
66. Jarosinski PF, Moscow JA, Alexander MS, Lesko LJ, Balis FM, Poplack DG. Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia. J Pediatr 1988;112:996-9.
67. Korstanje MJ, van Breda Vriesman CJ, van de Staak WJ. Cyclosporine and methotrexate: a dangerous combination. J Am Acad Dermatol 1990;23:320-1.
68. Fox R, Morgan S, Smith H, et al. Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology 2003;42:6.
69. Nierenberg DW, Mamelok RD. Toxic reaction to methotrexate in a patient receiving penicillin and furosemide: a possible interaction. Arch Dermatol 1983;119:449-50.
70. Mayall B, Poggi G, Parkin JD. Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal. Med J Aust 1991;155:480-4.
71. Dean R, Nachman J, Lorenzana AN. Possible methotrexate-mezlocillin interaction. Am J Pediatr Hematol Oncol 1992;14:88-9.
72. Ronchera CL, Hernandez T, Peris JE, et al. Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther Drug Monit 1993;15:375-9.
73. Yamamoto K, Sawada Y, Matsushita Y, Moriwaki K, Bessho F, Iga T. Delayed elimination of methotrexate associated with piperacillin administration (letter). Ann Pharmacother 1997;31:1261-2.
74. Titier K, Lagrange F, Pehourcq F, Moore N, Molimard M. Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther Drug Monit 2002;24:570-2.
75. Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet 1986;1:1390.
76. Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986;1:256-8.
77. Singh RR, Malaviya AN, Pandey JN, Guleria JS. Fatal interaction between methotrexate and naproxen. Lancet 1986;1:1390.
78. Stockley IH. Methotrexate-NSAID interactions (letter). Drug Intell Clin Pharm 1987;21:546.
79. Dupuis LL, Koren G, Shore A, Silverman ED, Laxer RM. Methotrexate- nonsteroidal antiinflammatory drug interaction in children with arthritis. J Rheumatol 1990;17:1469-73.
80. Kraus A, Alarcon-Segovia D. Low dose MTX and NSAID induced "mild" renal insufficiency and severe neutropenia. J Rheumatol 1991;18:1274.
81. Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 1992;26:234-7.
82. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992;42:121-5.
83. Zachariae H. Methotrexate and non-steroidal anti-inflammatory drugs. Br J Dermatol 1992;126:95.
84. Small RE, Redford TW. Is methotrexate interaction critical? Am Pharm 1994;NS34:3-4.
85. Tracy TS, Worster T, Bradley JD, Greene PK, Brater DC. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1994;37:453-6.
86. Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995;22:2072-7.
87. Franck H, Rau R, Herborn G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol 1996;15:266-70.
88. Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1999;26:2539-43.
89. Schwartz JI, Agrawal NG, Wong PH, et al. Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. J Clin Pharmacol 2001;41:1120-30.
90. Liegler DG, Henderson ES, Hahn MA, Oliverio VT. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 1969;10:849-57.
91. Baker H. Intermittent high dose oral methotrexate therapy in psoriasis. Br J Dermatol 1970;82:65-9.
92. Mandel MA. The synergistic effect of salicylates on methotrexate toxicity. Plast Reconstr Surg 1976;57:733-7.
93. Taylor JR, Halprin KM. Effect of sodium salicylate and indomethacin on methotrexate-serum albumin binding. Arch Dermatol 1977;113:588-91.
94. Furst DE, Herman RA, Koehnke R, et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 1990;79:782-6.
95. Legier UF, Benet LZ. Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives. Clin Pharmacol Ther 1986;39:425-9.
96. Kobrinsky NL, Ramsay NK. Acute megaloblastic anemia induced by high-dose trimethoprim-sulfamethoxazole. Ann Intern Med 1981;94:780-1.
97. Dan M, Shapira I. Possible role of methotrexate in trimethoprim- sulfamethoxazole-induced acute megaloblastic anemia. Isr J Med Sci 1984;20:262-3.
98. Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 1986;13:440-1.
99. Maricic M, Davis M, Gall EP. Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment. Arthritis Rheum 1986;29:133-5.
100. Frain JB. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 1987;14:176-7.
101. Slordal L, Sager G, Aarbaklce J. Pharmacokinetic interactions with methotrexate: is 7-hydroxy-methotrexate the culprit? Lancet 1988;1:591-2.
102. Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia and methotrexate with trimethoprim-sulfamethoxazole. Ann Intern Med 1989;111:261.
103. Ferrazzini G, Klein J, Sulh H, Chung D, Griesbrecht E, Koren G. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 1990;117:823-6.
104. Groenendal H, Rampen FH. Methotrexate and trimethoprim-sulphamethoxazole - a potentially hazardous combination. Clin Exp Dermatol 1990;15:358-60.
105. Bourke RS, Chheda G, Bremer A, Watanabe O, Tower DB. Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res 1975;35:110-6.
106. Kates RE, Tozer TN. Biliary secretion of methotrexate in rats and its inhibition by probenecid. J Pharm Sci 1976;65:1348-52.
107. Kates RE, Tozer TN, Sorby DL. Increased methotrexate toxicity due to concurrent probenecid administration. Biochem Pharmacol 1976;25:1485-8.
108. Aherne GW, Piall E, Marks V, Mould G, White WF. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J 1978;1:1097-9.
109. Howell SB, Olshen RA, Rice JA. Effect of probenecid on cerebrospinal fluid methotrexate kinetics. Clin Pharmacol Ther 1979;26:641-6.
110. Lilly MB, Omura GA. Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid. Cancer Chemother Pharmacol 1985;15:220-2.
111. Evans WE, Christensen ML. Drug interactions with methotrexate. J Rheumatol Suppl 1985;12(suppl 12):15-20.
112. Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol 1991;18:609-10.
113. Millikan CH, Eaton LM. Clinical-evaluation of ACTH and cortisone in myasthenia gravis. Neurology 1951;1:145-52.
114. Grob D, Harvey AM. Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration. Bull Johns Hopkins Hosp 1952;91:124-36.
115. Warmolts JR, Engel WK, Whitaker JN. Alternate-day prednisone in a patient with myasthenia gravis. Lancet 1970;2:1198-9.
116. Brunner NG, Namba T, Grob D. Corticosteroids in management of severe, generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy. Neurology 1972;22:603-10.
117. Namba T, Shapiro MS. Corticotropin therapy in patients with myasthenia gravis: steroid metabolism, and histology of skeletal muscle and thymus. J Neurol Sci 1972;16:165-76.
118. Patten BM, Oliver KL, Engel WK. Adverse interaction between corticosteroid hormones and anticholinesterase drugs. Trans Am Neurol Assoc 1973;98:248-52.
119. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 1989;45:366-72.
120. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000;56:57-60.
121. Kuntzman R, Jacobson M, Levin W, Conney AH. Stimulatory effect of N-phenylbarbital (phetharbital) on cortisol hydroxylation in man. Biochem Pharmacol 1968;17:565-71.
122. Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med 1972;286:1125-8.
123. Stjernholm MR, Katz FH. Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. J Clin Endocrinol Metab 1975;41:887-93.
124. Brooks PM, Buchanan WW, Grove M, Downie WW. Effects of enzyme induction on metabolism of prednisolone. Clinical and laboratory study. Ann Rheum Dis 1976;35:339-43.
125. Hancock KW, Levell MJ. Primidone/dexamethasone interaction. Lancet 1978;2:97-8.
126. Gabrielsen J, Bendtsen A, Eriksen H, Andersen S. Methylprednisolone half-life during simultaneous barbiturate treatment and mechanical hyperventilation of neurosurgical patients. J Neurosurg 1985;62:182-5.
127. Young MC, Hughes IA. Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone. Acta Paediatr Scand 1991;80:120-4.
128. Petereit LB, Meikle AW. Effectiveness of prednisolone during phenytoin therapy. Clin Pharmacol Ther 1977;22:912-6.
129. McLelland J, Jack W. Phenytoin/dexamethasone interaction: a clinical problem. Lancet 1978;1:1096-7.
130. Frey BM, Schaad HJ, Frey FJ. Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. Eur J Clin Pharmacol 1984;26:505-11.
131. Keilholz U, Guthrie GP Jr. Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. Am J Med Sci 1986;291:280-3.
132. Buffington GA, Dominguez JH, Piering WF, Hebert LA, Kauffman HM Jr, Lemann J Jr. Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA 1976;236:1958-60.
133. Hendrickse W, McKiernan J, Pickup M, Lowe J. Rifampicin-induccd non-responsiveness to corticosteroid treatment in nephrotic syndrome. Br Med J 1979;1:306.
134. Bergrem H, Refvem OK. Altered prednisolone pharmacokinetics in patients treated with rifampicin. Acta Med Scand 1983;213:339-43.
135. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) 1983;286:923-5.
136. Powell-Jackson PR, Gray BJ, Heaton RW, Costello JF, Williams R, English J. Adverse effect of rifampicin administration on steroid-dependent asthma. Am Rev Respir Dis 1983;128:307-10.
137. Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 1984;59:1204-6.
138. Carrie F, Roblot P, Bouquet S, Delon A, Roblot F, Becq-Giraudon B. Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. Arch Intern Med 1994;154:1521-4.
139. Klinenberg JR, Miller F. Effect of corticosteroids on blood salicylate concentration. JAMA 1965;194:601-4.
140. Graham GG, Champion GD, Day RO, Pauli PD. Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Clin Pharmacol Ther 1977;22:410-20.
141. Bardare M, Cislaghi GU, Mandelli M, Sereni F. Value of monitoring plasma salicylate levels in treating juvenile rheumatoid arthritis. Observations in 42 cases. Arch Dis Child 1978;53:381-5.
142. Edelman J, Potter JM, Hackett LP. The effect of intra-articular steroids on plasma salicylate concentrations. Br J Clin Pharmacol 1986;21:301-7.
143. Baer PA, Shore A, Ikeman RL. Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis. Arthritis Rheum 1987;30:345-7.
144. Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L. Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis. Ther Drug Monit 1987;9:177-9.
145. Day RO, Harris G, Brown M, Graham GG, Champion GD. Interaction of salicylate and corticosteroids in man. Br J Clin Pharmacol 1988;26:334-7.
146. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997;62:41-9.
147. Thomas PP, Manivannan J, John GT, Jacob CK. Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation 2004;77:474-5.
148. Kuypers DR, Claes K, Evenepoel P, et al. Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient. Transplantation 2005;79:737.
149. Said A, Garnick JJ, Dieterle N, Peres E, Abidi MH, Ibrahim RB. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006;26:289-95.
150. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:552-9.
151. Bottiger Y, Sawe J, Brattstrom C, et al. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther 2001;69:32-40.
152. Product information. Rapamune (sirolimus) oral solution and tablets. Philadelphia: Wyeth Pharmaceuticals Inc., 2005.
153. Johnson EM, Zimmerman J, Duderstadt K, et al. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 1996;28:987.
154. Ferron GM, Mishina EV, Zimmerman JJ, Jusko WJ. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther 1997;61:416-28.
155. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998;63:48-53.
156. Zimmerman JJ, Harper D, Getsy J, Jusko WJ. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol 2003;43:1168-76.
157. Cattaneo D, Merlini S, Pellegrino M, et al. Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 2004;4:1345-51.
158. Kovarik JM, Noe A, Wang Y, Mueller I, DeNucci G, Schmouder RL. Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus. Eur J Clin Pharmacol 2006;62:361-6.
159. Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998;64:648-54.
160. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002;87:933-7.
161. Martin K, Begaud B, Larry P, Miremont-Salame G, Fourrier A, Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 2004;57:86-92.
162. Pascual J, Diener HC, Massiou H. Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example. J Headache Pain 2006;7:27-33.
163. Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc (Wash) 2001;41:161-5.
164. Malone DC, Abarca J, Hansten PD, et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc (2003) 2004;44:142-51.
165. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80. Epub 27 Mar 2007. DOI 10.1345/aph.1H423